粒细胞集落刺激因子对供者外周血干细胞动员的影响

目的：探讨外周血造血干细胞移植（PBSCT）供者应用粒细胞集落刺激因子（G-CSF）后细胞成分的变化和药物对供者身体状况的近期影响。方法：对18例健康PBSCT供者应用一定剂量G-CSF,4-5d后采集外周血单个核细胞进行检测及观察用药后出现的不良反应。结果：外周血白细胞在动员后4-5 d达峰值,动员后比动员前高7-14倍。供者单个核细胞（MNC）和CD34^＋细胞值之间差异无统计学意义。结论：对PBSCT供者应用G-CSF 5-10μg/（kg.d）,4-5 d可有效动力员MNC和CD34^＋细胞。     

BU／CY预处理方案的异基因外周血干细胞移植治疗急性白血病

目的 :观察 BU / CY预处理方案的异基因外周血干细胞移植 (Allo- PBSCT)治疗急性白血病的疗效。方法 :用 BU / CY预处理方案行 Allo- PBSCT治疗急性白血病 5例 ,其中急性淋巴细胞白血病 (AL L ) 4例 (CR13例 ,CR2 1例 ) ,急性非淋巴细胞白血病 (ANL L) 1例 (CR1 )。预处理方案 BU/ CY:BU4m g/ (kg· d)× 4,CTX6 0m g/ (kg· d)× 2。其中 2例 AL L 分别加米托蒽醌 40～ 5 0 m g。用 G- CSF10 μg/ (kg· d)× 5 d进行造血干细胞动员 ,分离单个核细胞 (MNC)中位数 6 .48× 10 8/ kg〔(3.5～ 7.0 )× 10 8/ kg〕。 CD34+细胞中位数 6 .6× 10 6 / kg〔(4.0～9.6 6 )× 10 6 / kg〕。结果 :全部患者移植后均重建造血 ,粒细胞 >0 .5× 10 9/ L,中位数 13d;血小板 >30× 10 9/ L,中位数为 13d;血小板 >5 0× 10 9/ L,中位数为 15 d。发生迟发性出血性膀胱炎 1例 ,白血病复发死亡 1例 ,CMV肺炎死亡 1例。其余 3例分别无病生存 11、9、7个月。结论 :Allo- PBSCT具有造血重建快 ,采集干细胞方便 ,供者易接受等优点     

异基因清髓性与非清髓性造血干细胞移植治疗狼疮鼠的疗效比较

目的　比较用异基因清髓性干细胞移植 (Allo SCT)和非清髓性干细胞移植 (NST)方法治疗狼疮鼠的有效性及安全性。方法　NST组 2 2只BXSB鼠用fludarabine +环磷酰胺 (CTX)作预处理。Allo SCT组 2 2只BXSB小鼠用马利兰 +CTX作预处理 ,预处理后受者输入经粒细胞集落刺激因子 (G CSF)动员后的供者 (C5 7BL/ 6 )的外周血干细胞 ,用环孢素A(CsA)、甲氨蝶呤 (MTX)预防移植物抗宿主病 (GVHD) ,G CSF促进移植后的造血和免疫重建 ,流式细胞仪检测供者Sca 1+ 含量及移植后受者T淋巴细胞亚群 (CD3-CD5 + 、CD3+ CD5 + )的变化 ,甲基纤维素半固体培养法培养供者的粒 巨噬细胞集落形成单位 (GM CFU) ,PCR法对移植后BXSB鼠嵌合状态进行分析 ,直接免疫荧光法和光镜检测移植前后受者的肾病理变化。结果　G CSF动员后不同时间两组供者外周血单个核细胞 (MNC)、CD+ 34、GM CFU数差异无显普性 (P均 >0 0 5 ) ,G CSF动员后第 7天两组供者MNC、CD34+ 、GM CFU数达最佳水平 ,NST组白细胞下降最低值分别为 (0 6± 0 2 )× 10 9/L ,高于Allo SCT组的 (0 2± 0 1)× 10 9/L (P <0 0 5 ) ,白细胞上升至 1 0× 10 9/L的时间在NST组为 (17 5±6 3)d ,比Allo SCT组明显缩短 (P <0 0 5 ) ,尿蛋白从 转为 +或 -、抗dsDNA抗体滴     

异基因外周血造血干细胞移植治疗难治性白血病(附1例报告)

对 1例难治性急性粒 -单细胞白血病 (AML - M4 b)患者施行异基因外周血造血干细胞移植 (allo-PBSCT ) ,以 Cy/ TBI方案预处理后 ,输注 HL A完全相合的同胞供者经 G- CSF动员的外周血单个核细胞(PBMNCs) 9.0× 10 8/ kg,其中 CD34 细胞 6 .2 5× 10 6 / kg;移植物抗宿主病 (GVHD)的预防用 Cs A MTX方案。结果 : 15天时 ,外周血中性粒细胞 >0 .5× 10 9/ L,血小板 >5 0× 10 9/ L; 30天时 ,外周血三系均完全恢复正常。仅有 度皮肤 GVHD发生。认为对于难治性白血病 ,如有 HL A相合供者 ,应及早行异基因造血干细胞移植 (allo-HSCT)特别是 allo- PBSCT,具有受者造血与免疫功能重建快等优点     

分泌型与包涵体型粒细胞集落刺激因子对骨髓干细胞动员效率的比较

目的观察两种不同粒细胞集落刺激因子(G CSF)动员剂(分泌型与包涵体型)对急性心肌梗死(AMI)患者骨髓血干细胞动员效率。方法一组予以包涵体型G CSF(商品名惠尔血)300μg(包涵体型G CSF组),每日2次,皮下注射,连续5天;另一组予以分泌型G CSF(商品名金磊赛强)300μg(分泌型G CSF组),每日2次,皮下注射,连续5天。第6日经美国Baxter公司生产的CS3000PLUS血细胞分离机,分离外周血干细胞,采集外周血干细胞悬液经流式细胞仪测定CD34+的细胞数量。结果给G CSF前及给G CSF后第3、4、5、6天两组间外周血中细胞表面标记蛋白CD34+细胞数量和白细胞计数无明显统计学差异;在应用两组不同的动员剂后,外周血中白细胞计数与动员时间变化曲线显示曲线高峰在动员后第5天;在包涵体型G CSF组,CD34+细胞数量与时间变化曲线高峰为第5天,但在分泌型G CSF组,CD34+细胞数量与时间变化曲线显示CD34+细胞数量在3～4天内呈急剧升高趋势,但在第5天后升幅明显减缓;显示分泌型G CSF组动员后外周血中干细胞下降较慢;患者外周血中CD34+细胞数量与白细胞计数变化呈正相关(r=0.835),与性别、体重、年龄及AMI发生时间无显著性相关。结论在AMI患者中应用两种不同G CSF动员剂,两组在外周血干细胞动员效率方面无明显统计学差异。     

伴海洋性贫血供者外周血造血干细胞采集效果分析

目的观察海洋性贫血供者外周血造血干细胞(PBSC)采集的效果。方法将2008年1月至2010年1月在中山大学附属第一医院血液内科接受PBSC采集的23例HLA全相合亲缘供者分为对照组(不伴海洋性贫血)15例,观察组(伴海洋性贫血)8例。比较两组供者PBSC动员后、采集前的血常规以及单次采集产品中血常规指标以及单个核细胞(MNC)计数和CD34+细胞计数,并观察两组在PBSC回输后造血重建情况。结果两组供者动员后、采集前的血常规中,WBC平均计数和MNC平均计数,比较差异均无统计学意义(P0.05);但在单次采集后,观察组RBC计数和HCT分别为(1.19±0.40)×1012/L和(0.084±0.032),明显高于对照组(0.79±0.17)×1012/L和(0.059±0.016)(P0.05),而WBC计数为(125.2±53.1)×109/L、MNC计数为(3.12±1.72)×108/kg和CD34+细胞平均计数为(1.25±0.69)×106/kg,则分别低于对照组的(220.4±25.1)×109/L、(5.87±1.36)×108/kg和3.52±0.82×106/kg(P0.05);观察组共行采集术13次、对照组供者各行1次采集。观察组MNC计数及CD34+细胞分别为(5.36±0.80)×108/kg和(2.14±0.32)×106/kg,与对照组比较差异均无统计学意义[(6.31±1.37)×108/kg和(3.79±0.82)×106/kg];PBSC回输后,观察组受者中性粒细胞和血小板的造血重建时间与对照组差异无统计学意义(P0.05)。结论海洋性贫血供者PBSC动员虽不受影响,但单次采集的PBSC产品中红细胞污染较重、MNC和CD34+细胞收获率降低,但适当增加采集次数后,其PBSC数量仍可达到移植要求,且不影响受者的造血重建。     

单个核细胞计数对异基因外周血干细胞移植后造血重建的预测研究

目的探讨单个核细胞(MNC)计数作为造血干(祖)细胞含量的独立指标预测异基因外周血干细胞移植(allo-PBSCT)后造血重建的可行性。方法将暨南大学附属第一医院血液科2000年1月至2008年12月120例allo-PBSCT患者分为MNC组(83例)和CD34+细胞组(37例),MNC组以≥4×108/kg为采集目标,CD34+细胞组以≥4×106/kgCD34+细胞为采集目标。比较两种计数指标对造血重建和供者采集次数的影响,并分析不同MNC剂量对造血重建的影响。结果MNC组受者输入MNC的中位数为6.81×108/kg,CD34+细胞组受者输入CD34+细胞的中位数为5.05×106/kg;两组造血重建率均为100%;两组中性粒细胞植活的中位时间均为移植后第11天(P0.05),血小板植活的中位时间均为移植后第12天(P0.05);两组供者1次采集率分别为100%和37.84%(P0.05);MNC组中HLA全相合与不全相合移植受者中性粒细胞植活的中位时间分别为移植后第11天和移植后第12天(P0.05),血小板植活的中位时间分别为移植后第12天和移植后第14天(P0.05);MNC剂量在(3～5.99)×108/kg递增时,剂量与造血重建呈正相关,而MNC剂量在达到6×108/kg后递增,则并未使植活时间随之进一步缩短。结论MNC计数单独作为造血干(祖)细胞含量的计数指标,不仅能可靠预示allo-PBSCT(包括HLA全相合与不全相合移植)后造血重建,其植活率和植活速度可与CD34+细胞相比拟,而且其供者1次采集率(100%)显著高于后者(37.84%),allo-PBSCT时MNC计数可取代CD34+细胞作为造血干(祖)细胞含量的独立指标。     

粒细胞集落刺激因子动员对CD34^＋细胞黏附分子表达的影响

目的探讨粒细胞集落刺激因子（G—CSF）动员对CD34^＋细胞黏附分子表达的影响。方法应用流式细胞仪检测健康供者稳态及G—CSF动员过程中骨髓、外周血CD34^＋细胞的黏附分子表达变化，并应用结晶紫染色测定CD34^＋细胞的黏附功能。结果G-CSF动员后CD34^＋CD49d^＋细胞比例无显著下降，外周血CD34^＋CD621．^＋、CD34^＋CD54^＋和CD34^＋CDlla^＋细胞比例增高。动员后CD34^＋细胞表面CD49d的平均荧光强度显著减弱，但CD49e、CD62L、CDlla、CD54的平均荧光强度虽呈减弱趋势，却无统计学差异。动员后CD34^＋细胞黏附纤连蛋白能力下降。结论G—CSF通过降低造血干细胞与骨髓基质的黏附而产生动员效应。     

儿童难治性自身免疫性疾病自体外周血干细胞动员采集和分选的临床研究

目的 探讨儿童难治性自身免疫性疾病进行自体外周血干细胞动员采集的安全性和CD34+细胞分选纯化的可行性及其临床意义.方法 8例儿童难治性自身免疫性疾病,包括4例系统性红斑狼疮、2例皮肌炎,1例幼年型类风湿关节炎和1例多发性硬化,予行CD34+细胞纯化的自体外周血干细胞移植.首先采用环磷酰胺(CTX)联合粒细胞集落刺激因子(G-CSF)方案动员外周血干细胞,然后采用CS-3000血细胞分离机采集外周血,通过CliniMACS细胞分选仪分选自体外周血CD34+细胞,将其用保养液配置冻存于-80℃冰箱.采用非清髓内去除T的预处理方案,即卡氮芥+足叶乙苷+阿糖胞苷+马法兰+抗胸腺球蛋白(ATG)或CTX+ATG或CTX+马法兰+ATG,于第0天回输自体外周血CD34+细胞.结果 儿童能够耐受自体外周血干细胞动员采集过程,无动员相关死亡,动员后获得的单个核细胞数和CD34+细胞数的平均值分别为8.35×108/kg和7.92×106/kg,纯化后的白体外周血CD34+和CD3+细胞数的平均值分别为6.28×106/kg和0.71×105/kg.回输后中性粒细胞和血小板的植入中位时间分别为+11d和+15 d.结论 经CTX联合G-CSF方案可动员出足量的外周血干细胞,经CS-3000血细胞分离机采集可获得足够的单个核细胞,在动员过程中原发病无明显进展恶化,患儿能耐受动员方案,采集过程顺利安全;经CliniMACS细胞分选仪分选的自体外周血CD34+细胞纯度高,移植后造血恢复;采用CD34+细胞纯化的自体外周血移植治疗是常规治疗无效的儿童难治性自身免疫性疾病的可选择治疗措施之一.     

大剂量环磷酰胺联合粒细胞集落刺激因子动员多发性骨髓瘤造血干细胞的价值研究

目的研究大剂量环磷酰胺(HD-CTX)联合粒细胞集落刺激因子(G-CSF)在多发性骨髓瘤(MM)造血干细胞动员中的临床疗效和安全性。方法选择2006年6月至2010年9月中山大学附属第一医院血液科36例MM患者,全部患者接受HD-CTX联合G-CSF动员,CTX 3~5 g/m2,第1天,G-CSF300μg/d第2天起直到干细胞采集结束。结果 35例(97.2%)动员成功,其中31例第一次动员即成功,4例第二次动员成功。干细胞采集的中位时间为第11(9~13)天,22例(62.9%)患者采集1次,13例(37.1%)患者采集2次。采集的单个核细胞(MNC)数为(4.49±1.71)×108/kg,CD34+细胞数为(3.21±1.87)×106/kg。7例疗效在动员后得到进一步提高。动员的非血液系统副反应包括恶心、呕吐11例(26.8%)、腹痛腹泻5例(12.2%)、发热7例(17.1%)、骨痛4例(9.8%)等。只有1例因感染影响干细胞采集。结论 HD-CTX联合G-CSF是MM造血干细胞动员的安全有效的方法。     

Aortitis after G-CSF injections

INTRODUCTION: Aortitis consists in aortic wall inflammation from infectious or non infectious cause. It may lead to aortic aneurysm with a risk of rupture, which is life-threatening and may justify surgical procedures. The cause of the aortitis is sometimes obscure. CASE REPORT: We report the case of a 55 years old woman who developed acute aortitis of the descending aorta after G-CSF (granulocyte-colony stimulating factor) injections for blood stem cells graft. No cause was found to the aortitis, the evolution was favorable after corticosteroid treatment, without aneurysm at six months. CONCLUSION: The present case rises the question of G-CSF (Neupogen responsibility in aortic lesions. Neutrophilic mediated diseases (Sweet's syndrome, pyoderma gangrenosum) and leukocytoclastic vasculitis were reported after G-CSF therapy. Neutrophils induced by G-CSF injections present functional abnormalities which may play a role in the pathogenesis of these diseases.     

Sweet's syndrome associated with G-CSF

Summary. Sweet's syndrome (SS) developed in two patients with acute myeloid leukaemia (AML) treated with granulocyte colony stimulating factor (G-CSF) for febrile neutropenia due to AML chemotherapy. Fever, painful skin and conjunctival lesions developed and neutrophilic infiltration was detected at biopsy specimens. Neutrophilia was not detected. Skin lesions regressed within 1–2 weeks and conjunctival lesions within 4 weeks following the cessation of G-CSF. We conclude that SS may be a complication of G-CSF therapy and tender skin and/or conjunctival lesions developing during G-CSF therapy should suggest the possibility of SS.     

Profound thrombocytopenia related to G-CSF

Severe thrombocytopenia in association with G-CSF therapy is extremely rare. Here we report a case of profound thrombocytopenia in a 57-year-old male with refractory cardiac ischemia, who received G-CSF during an angiogenesis trial. After 5 days of G-CSF therapy (10 microg/kg/day) the platelet count fell progressively to a nadir of 5x10(9)/L. The patient received steroid, immunoglobulin and platelet support and recovered without sequelae. Subsequent investigations suggested an underlying immune-mediated thrombocytopenia, which we hypothesize was exacerbated by G-CSF therapy.     

Granulocyte colony-stimulating factor (G-CSF) production and G-CSF receptor structure in patients with congenital neutropenia

Congenital neutropenia (Kostmann's syndrome [KS]) is an autosomal recessive syndrome that is characterized by profound neutropenia, resulting in major clinical infections and death. Since the neutropenia and symptoms in KS improve in response to exogenous administration of granulocyte colony-stimulating factor (G-CSF), we studied bone marrow cytokine (G-CSF, granulocyte-macrophage CSF [GM-CSF], and interleukin- 6) production under both basal and stimulated conditions. No differences in G-CSF, GM-CSF, or IL-6 gene expression were found in bone marrow stromal cells between normal controls and KS patients, and all three cytokines were detected by enzyme-linked immunosorbent assay (ELISA) in medium conditioned by bone marrow stromal cells from normal donors and patients with KS. Each KS patient tested had detectable, functional G-CSF in their own serum before exogenous G-CSF administration. Since G-CSF production appeared normal in KS patients, we then asked whether we could detect structural defects in the signaling portion of G-CSF receptor genes. Polymerase chain reaction (PCR) amplification of the G-CSF receptor transmembrane region alone, and of the transmembrane plus cytosolic portions of the receptor, yielded the size products predicted from the sequences of the normal G- CSF receptor. Single-strand conformational polymorphism (SSCP) analysis of G-CSF receptor PCR products demonstrated no variance in structural conformation between KS patients and normal subjects. These results demonstrate that bone marrow stromal cells in patients with KS secrete normal concentrations of functional G-CSF and suggest that the neutropenia in KS patients is caused by an inability of neutrophilic progenitor and precursor cells to respond to normal, physiologic levels of G-CSF. Such a defect, clinically responsive to pharmacologic doses of G-CSF, might be caused by defects in the post-G-CSF receptor signal transduction pathway.     

Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone

Dendritic cells (DCs) are antigen-presenting cells that are critical to the generation of immunologic tumor responses. Myeloid DCs (DC1) express myeloid antigen CD11c; lymphoid DCs (DC2) express CD123(+) and are CD11c(-). Analysis of DC subsets from peripheral blood progenitor cells (PBPC) collected from normal donors mobilized with G-CSF shows a predominance of DC2 cells. Whether PBPCs mobilization by chemotherapy yields different subsets of DCs has not been studied. We analyzed DC subsets in apheresis products from 44 patients undergoing autologous stem cell transplantation from 6/00 to 5/01. Patients received either G-CSF alone (10 microg/kg per day, n=11) or etoposide (2 g/m(2)) plus G-CSF (n=33) for progenitor cell mobilization. The patients were apheresed for 2-10 days (median 3) to reach a minimum of 2.0 x 10(6) CD34(+) cells/kg. Patients receiving G-CSF alone mobilized significantly more total DC2s than did those receiving etoposide plus G-CSF (median 6.2 x 10(6)/kg vs 2.9 x 10(6)/kg, P=0.001). The DC2/DC1 ratio was also significantly different in the two groups, with the G-CSF group having a higher ratio (median 1.2 vs 0.4, P<0.001). We conclude that the combination of chemotherapy plus G-CSF yields different mobilized dendritic cell subsets than does G-CSF alone.     

Severe congenital neutropenia unresponsive to G-CSF

Summary Severe congenital neutropenia (SCN) is an inherited disorder characterized by severe neutropenia and recurrent infections from an early age, with bone marrow showing a maturational arrest of granulopoiesis at the promyelocyte stage. Since the introduction of G-CSF therapy the prognosis for affected children has improved dramatically. We describe two patients with SCN who were clinically unresponsive to G-CSF therapy. The results of in-vitro colony assays from these two patients are presented together with the results from the mother of one of these patients who also has a chronic neutropenia, and a further child with SCN who responded to treatment with G-CSF.